Drug Profile
Carfilzomib - Onyx Pharmaceuticals
Alternative Names: Kyprolis; ONO-7057; PR-171Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Proteolix
- Developer AbbVie; Amgen; Dana-Farber Cancer Institute; Genentech; GSK; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California at San Francisco; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Marketed Multiple myeloma
- Phase III Waldenstrom's macroglobulinaemia
- Phase II Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma
- Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
- No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
Most Recent Events
- 12 Apr 2024 Amgen and Arbeitsgemeinschaft medikamentoese Tumortherapie completes a phase II trial in Multiple myeloma (Combination therapy, First line therapy) in Austria and Germany (NCT02891811) (EudraCT2016-000475-24)
- 07 Nov 2023 Stanford University and Amgen completes a phase-I trial in Solid Tumours and Leukaemia (In infants, children, Adolescents, In adults, Second-line therapy or greater)in Canada and USA (NCT02512926)
- 30 Oct 2023 Oncotherapeutics and Onyx terminates a phase II trial for Multiple myeloma (Second-line therapy or greater) in USA due to the difficulties to enroll patients (NCT02294357)